Latest News

• Biomarker Testing for Brain Cancer!        

   New article added to our website, listing testing options.  A must read if you will be having a surgery or biopsy soon.  

  
  
• Press Release IB awarded a $100,000 grant by the Musella Foundation        

   We awarded a $100,000 grant to get this expanded access program for oral gallium maltolate launched.  I will let you know when it opens.  We helped fund the early work on this drug and early results look good.  If interested in trying to get access, send an email to eap@imagingbiometrics.com and tell them a little about your case and ask if you may qualify for the program and to get on the waiting list.   Our grant only covers PART of the costs of this program - and enabled getting it opened. Patients will be charged a portion of the costs.      If any other organizations want to help fund the full program to make it free to patients,  contact me!  We are working on creating a fund to help offset these cost - will let you know details when ready!

  
  
• Copayment Assistance Program update!        

   We increased our income guidelines - see the website for details but for a family of 4, we now allow up to $156,000 in income!   We also take into account if you will make less money due to the tumor.

  
  
• Webinar on Sonodynamic Therapy For Brain Tumors this Wednesday!        

  Sonodynamic therapy is an exciting, non-invasive experimental treatment for brain tumors. I think it will be shown to be a breakthrough and will significantly impact this disease. This webinar is at a different date and  time than usual - we wanted to get it to you as soon as possible!  

  
  
• IN8bio Announces Publication on Novel Gamma-Delta T Cell Therapy for Glioblastoma in Frontiers in Immunology        

   Interesting new approach to treating glioblastoma. Very early results look good! Will keep an eye on this.

  
  
• Northwest Biotherapeutics Moves From Optimization of Flaskworks Prototype to Fabrication of GMP-Compliant Units For Installation, Validation and Final Testing Prior to Regulatory Certification        
  This announcement heralds significant progress in the realm of personalized medical treatments, a field historically challenged by the dual hurdles of scaling production and managing costs effectively. The bespoke nature of custom-made therapies, while groundbreaking, has led to exorbitant prices and a notable scarcity, compelling physicians to allocate these life-saving treatments to only the most critically ill patients. The traditional method of meticulously crafting each treatment individually is far from efficient.
   
  However, Northwest Bio's recent breakthrough introduces a game-changing solution. They have developed a machine capable of automating this intricate process, enabling the simultaneous creation of vaccines for multiple patients. Remarkably, this innovation also eliminates the need for the sterile environments mandated by manual production methods. This advancement is poised to significantly streamline the production of DCVAX, when it receives approval, meeting any level of demand with newfound ease.
  
  
• Ivy Center Announces First Patient Treated in Targeted Phase 0/1 Clinical Trial for High-Grade Glioma        

   This is a new generation of EGFR inhibitor that gets through the blood brain barrier and targets multiple mutations in EGFR.    Worth looking into if your pathology report showed alterations in EGFR!

  
  
• Brain cancer a thing of the past?        
  It's far too premature to determine the efficacy of this treatment, as it has not yet been tested in animals or humans. Experience has shown that many treatments effective in lab settings fail in human clinical trials. The purpose of sharing this article is to highlight the development process of a new lab-proven treatment. The next steps typically involve further lab research, animal testing, and the challenging task of securing funding for human trials. Recently, we were approached for a grant to support an early-stage brain tumor treatment, which required a staggering $1 million per patient. Unfortunately, we had to decline due to financial constraints. The plan  was to treat approximately 250 patients in total over the next decade before seeking FDA approval, a venture that no one is eager to invest $250 million in, given the risks and the potential to become obsolete by the time approval is granted.
   
  I advocate for the Promising Pathway Act, which offers a more feasible approach. If the drug proves to be highly effective, it could undergo a small phase 1/2 trial with about 25 patients for an estimated $25 million, potentially receiving conditional FDA approval within three years. This would allow the drug to be accessible sooner, with continued research over eight years and costs covered by insurance or out-of-pocket payments. This method not only makes fundraising more manageable but also enables setting a reasonable price for the treatment, recovering the investment without the need for exorbitant pricing. This approach addresses the financial challenges of bringing new treatments to market.
  
  
• Biodexa Reports 12 Month Survival in MAGIC-G1 Study of MTX110 in Recurrent Glioblastoma Patients        

   This looks promising. Still too early to tell, but early results look good.